Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7151474 | 0.87 | KAT6A (0.78) | GAAKMT2AL3MBTL1KDM4EMEN1 | |
| SCHEMBL25872681 | 0.87 | KMT2A (0.71) | GAAKMT2AL3MBTL1KDM4EMEN1 | |
| SCHEMBL25241197 | 0.84 | KMT2A (0.71) | GAAKMT2AL3MBTL1KDM4EMEN1 | |
| SCHEMBL25872106 | 0.84 | KMT2A (0.71) | GAAKMT2AL3MBTL1KDM4EMEN1 | |
| SCHEMBL26104327 | 0.83 | MEN1 (1.00) | GAAKMT2AMEN1KAT6ABCAT1 | |
| SCHEMBL25872083 | 0.83 | GFER (0.91) | GAAKMT2AL3MBTL1MEN1KAT6A | |
| SCHEMBL25872786 | 0.83 | KMT2A (0.69) | GAAKMT2AL3MBTL1KDM4EMEN1 | |
| SCHEMBL25872095 | 0.81 | KMT2A (0.68) | GAAKMT2AL3MBTL1KDM4EMEN1 | |
| SCHEMBL25288758 | 0.81 | KMT2A (0.62) | GAAKMT2AL3MBTL1KDM4EMEN1 | |
| SCHEMBL25872350 | 0.80 | GAA (0.80) | GAAKMT2AMEN1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115715285-A | Compounds as UBR box domain ligands | 奧土择破利悟 | 2023-02-24 | — | — | CN | claimed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| CN-115715285-A | Compounds as UBR box domain ligands | 奧土择破利悟 | 2023-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | GAA 996/4885KMT2A 1391/4885L3MBTL1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.